The RAGE/multiligand axis: A new actor in tumor biology

20Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

Abstract

The receptor for advanced glycation end-products (RAGE) is a multiligand binding and single-pass transmembrane protein which actively participates in several chronic inflammation-related diseases. RAGE, in addition to AGEs, has a wide repertoire of ligands, including several damage-associated molecular pattern molecules or alarmins such as HMGB1 and members of the S100 family proteins. Over the last years, a large and compelling body of evidence has revealed the active participation of the RAGE axis in tumor biology based on its active involvement in several crucial mechanisms involved in tumor growth, immune evasion, dissemination, as well as by sculpturing of the tumor microenvironment as a tumor-supportive niche. In the present review, we will detail the consequences of the RAGE axis activation to fuel essential mechanisms to guarantee tumor growth and spreading.

Cite

CITATION STYLE

APA

Rojas, A., Schneider, I., Lindner, C., Gonzalez, I., & Morales, M. A. (2022, July 1). The RAGE/multiligand axis: A new actor in tumor biology. Bioscience Reports. Portland Press Ltd. https://doi.org/10.1042/BSR20220395

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free